BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,025 shares of the biopharmaceutical company’s stock after selling 6,236 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Alnylam Pharmaceuticals were worth $2,662,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Point72 Asset Management L.P. grew its stake in shares of Alnylam Pharmaceuticals by 921.6% during the first quarter. Point72 Asset Management L.P. now owns 908,046 shares of the biopharmaceutical company’s stock worth $108,148,000 after purchasing an additional 819,160 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $42,128,000. Baillie Gifford & Co. grew its stake in shares of Alnylam Pharmaceuticals by 10.4% during the second quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock worth $416,798,000 after purchasing an additional 397,668 shares in the last quarter. Farallon Capital Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $44,067,000. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $29,507,000. 93.39% of the stock is currently owned by institutional investors and hedge funds.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now owns 1,916 shares in the company, valued at $229,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Laurie Keating sold 1,563 shares of the stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $105.04, for a total transaction of $164,177.52. Following the sale, the senior vice president now owns 16,063 shares of the company’s stock, valued at approximately $1,687,257.52. The disclosure for this sale can be found here. Insiders have sold 54,063 shares of company stock valued at $5,733,678 in the last quarter. Insiders own 4.30% of the company’s stock.
ALNY has been the subject of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $180.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 3rd. BMO Capital Markets reiterated a “buy” rating and set a $127.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 3rd. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 21st. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Finally, Cowen restated a “buy” rating and issued a $157.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 2nd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $141.57.
NASDAQ ALNY opened at $109.00 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22. Alnylam Pharmaceuticals, Inc. has a 1 year low of $70.76 and a 1 year high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The company had revenue of $29.91 million during the quarter, compared to the consensus estimate of $16.96 million. During the same quarter in the prior year, the firm posted ($1.07) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 87.8% on a year-over-year basis. sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.08 EPS for the current year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: Determine Your Level of Risk Tolerance
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.